Canadian firm Tilray (NASDAQ:TLRY) has obtained the support of global leading brewer Anheuser-Busch InBev SA/NV (NYSE:BUD) to develop cannabis-infused beverages.

On Wednesday (December 19), the cannabis licensed producer (LP) confirmed a research partnership to create tetrahydrocannabinol (THC) and cannabidiol (CBD) infused non-alcoholic drinks for the Canadian adult-use market.


This new deal cements the added interest from the beverage and other established industries into the cannabis space.

Tilray and AB InBev will invest up to US$50 million in the new venture. The collaboration will be overseen by Tilray’s recreational subsidiary High Park and AB InBev’s subsidiary Labatt Breweries of Canada.

Kyle Norrington, president of Labatt Breweries of Canada, said in a statement the company wants to stand by “the highest standards of product quality and responsible marketing” as Canadians begin consuming these beverages.

Edibles and infused products are scheduled to become legal in Canada at some point in 2019.

Brendan Kennedy, CEO of Tilray, said he was delighted for this partnership and will strive for a responsible approach to the creation and promotion of these drinks.

Shares of Tilray dropped during Wednesday’s trading session by 7.19 percent to a closing price of US$71 per share.

However, during after hours trading, the stock jumped up 10.49 percent for a price of US$78.45.

Meanwhile, shares of the parent company for AB InBev in New York rose a marginal 0.29 percent on after hours trading. Over a year-to-date period, stock of the beverage company has dropped nearly 40 percent.

The pursuit of the cannabis-infused beverage market is a crowded one with several leading LPs aspiring to serve this market, while a plenitude of smaller companies have also shares intentions to offer beverages.

Most notably, Canopy Growth (NYSE:CGC,TSX:WEED) and Hexo (TSX:HEXO) previously obtained partnerships with large beverage companies Constellation Brands (NYSE:STZ) and Molson Coors Brewing (NYSE:TAP,TSX:TAP).

Kris Dahl, VP of corporate development with Sproutly Canada (CSE:SPR), a company entirely focused on technologies for cannabis beverages, previously told the Investing News Network (INN) the problem with current cannabis beverages is it can take up to 30 or 45 minutes for the effects to kick in.

“Some people are impatient looking for that effect so they drink too much and when it finally hits, they are out of it for a long, long time,” Dahl said.

Similar to Hexo’s deal with Molson, Tilray’s joint venture will be managed by both the cannabis and beverage firms.

Unlike Constellation’s C$5 billion investment into Canopy, no shares or stake in the cannabis company are being exchanged in Tilray’s arrangement with its beverage partner.

Kennedy told the the Globe and Mail Tilray’s is not looking to be acquired at the moment and prefers the research deal in place.

This new deal comes on the heels of a new collaboration agreement between Tilray and generic pharmaceutical company Sandoz AG, a member of the Novartis (NYSE:NVS) group.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less